Searching News Database: Advair
HSMN NewsFeed - 17 Aug 2020
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent(R) Diskus(R)
Lannett Signs Agreement To Be Exclusive Distributor Of Generic Flovent(R) Diskus(R)
HSMN NewsFeed - 30 Oct 2015
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business
Mylan Appoints Ranjan Ray Chaudhuri as Global Commercial Lead for Mylan's Over-the-Counter Business
HSMN NewsFeed - 28 Sep 2012
Seebri(R) Inhalation Capsules Receive MHLW Approval as Once-daily Maintenance Treatment for COPD in Japan
Seebri(R) Inhalation Capsules Receive MHLW Approval as Once-daily Maintenance Treatment for COPD in Japan
HSMN NewsFeed - 24 Feb 2011
Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
Pearl Therapeutics Appoints Charles (Chuck) Bramlage President and Chief Executive Officer
HSMN NewsFeed - 11 Feb 2010
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
Abbott Receives U.S. FDA Approval for Heat-Stable Norvir(R) (ritonavir) Tablets
HSMN NewsFeed - 8 Jan 2010
Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations
Talecris Biotherapeutics Appoints Drayton Virkler as Senior Director, Investor Relations
HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
HSMN NewsFeed - 21 May 2008
Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50
HSMN NewsFeed - 30 Apr 2008
FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD
HSMN NewsFeed - 27 Dec 2007
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee
HSMN NewsFeed - 5 Dec 2007
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program
HSMN NewsFeed - 10 Aug 2007
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical Officer
MAP Pharmaceuticals Promotes Stephen B. Shrewsbury to Position of Chief Medical Officer
HSMN NewsFeed - 31 Jul 2007
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer
Additional items found! 18
Members Archive contains
18 additional stories matching:
Advair
(Password required)
Advair
(Password required)